A Case of Amylase-producing Lung Cancer Diagnosed by Transbronchial Curettage

Uno, Tomoyasu; Mochizuki, Hirofumi; Okada, Tadahiko; Yoshizawa, Hirohisa; Suzuki, Eiichi; Gejyo, Fumitake

doi:10.2482/haigan.43.715

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6,7 Minami et al 2 and Kitagawa et al 3 reported the serum amylase levels to be a potentially useful tumor marker for both the diagnosis of lung cancer and the follow-up. On the other hand, Uno et al 8 reported that the serum amylase levels were not associated with the disease. However, the clinical effi cacy of this tumor marker remains controversial because some previous studies have shown that the level of amylase synthesized in the tumor tissue does not correlate with hyperamylasemia.…”

Section: Discussionmentioning

confidence: 97%

Serum amylase is a sensitive tumor marker for amylase-producing small cell lung cancer?

et al. 2007

View full text Add to dashboard Cite

A 68-year-old male smoker was diagnosed as having amylase-producing small-cell lung cancer (SCLC). The serum amylase level was elevated, at 1756 IU/l, and the isozyme pattern was salivary type. Serum levels of "the tumor markers" CEA and NSE were 10.0 ng/ml and 22.6 ng/ml, respectively, but the level of pro-GRP was within the normal range. He was treated with combination chemotherapy of carboplatin and irinotecan. After completion of the chemotherapy, the serum amylase level decreased below the cutoff range and a computed tomography (CT) scan of the chest revealed marked reductions of the tumor in the primary site and in the lymph node metastasis. In November 2003, he was noted to have a slightly raised amylase level, of 168 IU/l, and raised levels of tumor markers. At this time, a CT scan, bone scintigraphy, and magnetic resonance imaging (MRI) of the brain demonstrated no recurrence. However, in December, MRI of the brain showed multiple metastases, and the recurrence of SCLC was thus confirmed. For the treatment of disease progression, the same regimen of chemotherapy as that given initially was administered. CT imaging revealed a partial response in the primary site and lymph node metastasis, and the serum amylase level decreased to 91 IU/l. After the completion of the second chemotherapy regimen, he underwent cranial irradiation and further chemotherapy. However, unfortunately, he died owing to deterioration of lung cancer. In this patient, the serum amylase level was found to be a highly sensitive marker of lung cancer.

show abstract

Section: Discussionmentioning

confidence: 97%

Serum amylase is a sensitive tumor marker for amylase-producing small cell lung cancer?

et al. 2007

View full text Add to dashboard Cite

show abstract

“…[21][22][23] Minami et al 13 and Kitazawa et al 24 reported the serum amylase levels to be a potentially useful tumour marker for both the diagnosis of lung cancer and the follow-up. On the other hand, Uno et al 25 reported that the serum amylase levels were not associated with the severity of the disease. However, the clinical efficacy of this tumour marker remains controversial because some previous studies have shown that the level of amylase synthesized in the tumour tissue does not correlate with hyperamylasaemia.…”

Section: Discussionmentioning

confidence: 97%

“…On the other hand, Uno et al. 25 reported that the serum amylase levels were not associated with the severity of the disease. However, the clinical efficacy of this tumour marker remains controversial because some previous studies have shown that the level of amylase synthesized in the tumour tissue does not correlate with hyperamylasaemia.…”

Section: Discussionmentioning

confidence: 97%

Hyperamylasaemia and dual paraneoplastic syndromes in small cell lung cancer

et al. 2013

View full text Add to dashboard Cite

We hereby describe the rare case of a 59-year-old patient presenting with marked hyperamylasaemia mimicking acute pancreatitis upon admission. Investigation of co-existent hypokalemia revealed the presence of ectopic adrenocorticotropic hormone secretion, leading to the final diagnosis of small cell lung cancer, exhibiting dual paraneoplastic syndromes including Cushing Syndrome and hyperamylasaemia. Although, paraneoplastic syndromes occur commonly, paraneoplastic hyperamylasaemia especially in the context of dual paraneoplastic syndromes occurring simultaneously, is extremely rare. Such misleading manifestations require a high index of suspicion on behalf of the physician, so that an underlying malignancy is not missed, and a final diagnosis combining all clinical and laboratory findings is reached. In turn, in rare cases common biochemical markers such as amylase can be used as a useful follow up index driving further management.

show abstract

“…Yoshida et T a b l e 2 . Ca s e -r e p o r t s o f Hy p e r a my l a s e mi a As s o c i a t e d wi t h S ma l l Ce l l L u n g Ca r c i n o ma endocrine-like granules in an SCLC case with hyperamylasemia (13 In patients with amylase-producing malignancies, hyperamylasemia may serve as a useful tumor marker (16,17,21 …”

Section: Discussionmentioning

confidence: 99%